ESMO 2022 | Incorporating immunotherapy and radiotherapy in Merkel cell carcinoma treatment regimens

Sungjune Kim, MD, PhD, Moffitt Cancer Center, Tampa, FL, discusses the efficacy of combining immunotherapy and radiotherapy to treat Merkel cell carcinoma. Despite ipilimumab and nivolumab alone producing robust responses, stereotactic body radiotherapy (SBRT) and immunotherapy have failed to produce similar outcomes. Whilst this may be caused by poor trial design, various strategies such as using alternative immunotherapies and dose fractionation may result in more successful treatment strategies involving immunotherapy and radiotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.